Literature DB >> 1320562

Circulating antigen KL-6 and lactate dehydrogenase for monitoring irradiated patients with lung cancer.

N Kohno1, H Hamada, S Fujioka, K Hiwada, M Yamakido, M Akiyama.   

Abstract

To determine the sensitivity of serum KL-6 and serum lactate dehydrogenase for detecting the contraction of radiation pneumonitis, 15 patients with lung cancer who had radiation therapy were monitored. Six of the patients contracted radiation pneumonitis (pneumonitis group) and the other patients did not (control group). Serum levels of KL-6 were significantly (p less than 0.05) elevated according to the complication of radiation pneumonitis in all patients of the pneumonitis group. In the control group, however, one-sided changes of KL-6 level were not observed. In the pneumonitis group, serum LDH levels were not significantly changed. However, there was a strong correlation between the altered levels of KL-6 and those of LDH (r = 0.992). These observations indicate that the same cytopathologic changes may cause the elevation of serum KL-6 level and the elevated activity of serum LDH in the patients with radiation pneumonitis, and that KL-6 is much more sensitive than LDH for detecting radiation pneumonitis.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320562     DOI: 10.1378/chest.102.1.117

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  11 in total

1.  Simultaneous measurements of KL-6 and SP-D in patients undergoing thoracic radiotherapy.

Authors:  Yosuke Matsuno; Hiroaki Satoh; Hiroichi Ishikawa; Takahide Kodama; Morio Ohtsuka; Kiyohisa Sekizawa
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

2.  Sequential changes of KL-6 in sera of patients with interstitial pneumonia associated with polymyositis/dermatomyositis.

Authors:  S Bandoh; J Fujita; Y Ohtsuki; Y Ueda; S Hojo; M Tokuda; H Dobashi; N Kurata; T Yoshinouchi; N Kohno; J Takahara
Journal:  Ann Rheum Dis       Date:  2000-04       Impact factor: 19.103

3.  KL-6 as a Biomarker of Interstitial Lung Disease Development in Patients with Sjögren Syndrome: A Retrospective Case-Control Study.

Authors:  Yu-Hsiang Chiu; Chen-Chih Chu; Chun-Chi Lu; Feng-Cheng Liu; Shin-En Tang; Shi-Jye Chu; San-Yuan Kuo; Hsiang-Cheng Chen
Journal:  J Inflamm Res       Date:  2022-04-08

4.  Circulating KL-6 levels in patients with drug induced pneumonitis.

Authors:  H Ohnishi; A Yokoyama; Y Yasuhara; A Watanabe; T Naka; H Hamada; M Abe; K Nishimura; J Higaki; J Ikezoe; N Kohno
Journal:  Thorax       Date:  2003-10       Impact factor: 9.139

5.  Change in serum KL-6 level from baseline is useful for predicting life-threatening EGFR-TKIs induced interstitial lung disease.

Authors:  Shigeo Kawase; Noboru Hattori; Nobuhisa Ishikawa; Yasushi Horimasu; Kazunori Fujitaka; Osamu Furonaka; Takeshi Isobe; Seigo Miyoshi; Hironobu Hamada; Takashi Yamane; Akihito Yokoyama; Nobuoki Kohno
Journal:  Respir Res       Date:  2011-07-26

Review 6.  Serum biomarkers in interstitial lung diseases.

Authors:  Argyris Tzouvelekis; George Kouliatsis; Stavros Anevlavis; Demosthenes Bouros
Journal:  Respir Res       Date:  2005-07-21

Review 7.  Serum biomarkers in acute respiratory distress syndrome an ailing prognosticator.

Authors:  Argyris Tzouvelekis; Ioannis Pneumatikos; Demosthenes Bouros
Journal:  Respir Res       Date:  2005-06-22

8.  Exceptionally high incidence of symptomatic grade 2-5 radiation pneumonitis after stereotactic radiation therapy for lung tumors.

Authors:  Hideomi Yamashita; Keiichi Nakagawa; Naoki Nakamura; Hiroki Koyanagi; Masao Tago; Hiroshi Igaki; Kenshiro Shiraishi; Nakashi Sasano; Kuni Ohtomo
Journal:  Radiat Oncol       Date:  2007-06-07       Impact factor: 3.481

9.  Analysis of predictive parameters for the development of radiation-induced pneumonitis.

Authors:  Toru Yamagishi; Norio Kodaka; Yoshiyuki Kurose; Kayo Watanabe; Chihiro Nakano; Kumiko Kishimoto; Takeshi Oshio; Kumiko Niitsuma; Hiroto Matsuse
Journal:  Ann Thorac Med       Date:  2017 Oct-Dec       Impact factor: 2.219

10.  A new serum tumor marker, CAM 123-6, highly specific to pulmonary adenocarcinoma.

Authors:  H Hamada; N Kohno; K Hiwada
Journal:  Jpn J Cancer Res       Date:  1994-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.